Suppr超能文献

卡马西平在大鼠体内的生物活化。活性芳烃氧化物形成的证据。

Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s).

作者信息

Madden S, Maggs J L, Park B K

机构信息

Department of Pharmacology and Therapeutics, University of Liverpool, UK.

出版信息

Drug Metab Dispos. 1996 Apr;24(4):469-79.

PMID:8801063
Abstract

The metabolism of carbamazepine (CBZ) and its major metabolite in humans, carbamazepine 10,11-epoxide (CBZ-E), was examined in the rat in vivo. Particular emphasis was placed on the identification of dihydrohydroxythio adducts, which are detoxication products of reactive arene oxide intermediates. Anesthetized and cannulated male Wistar rats were administered [3H]CBZ (25 micrograms.kg-1 or 25 mg.kg-1) or [3H]CBZ-E (25 micrograms.kg-1 or 25 mg.kg-1) intravenously and bile and urine collected for 5 hr. Less than 8% of drug was excreted in the urine for each dosing regimen. Biliary excretion accounted for 73.7 +/- 6.2 and 41.8 +/- 6.2% (mean +/- SD, N = 4) of administered CBZ (25 micrograms.kg-1 and 25 mg.kg-1, respectively) and 47.6 (N = 2) and 28.1 +/- 6.0% of administered CBZ-E (25 micrograms.kg-1 and 25 mg.kg-1, respectively). The major route of metabolism of both CBZ and CBZ-E was N-glucuronidation. In rats given CBZ (25 mg.kg-1), the N-glucuronide of the parent compound accounted for 12.6 +/- 2.6% of the dose, whereas CBZ-E N-glucuronide accounted for 12.3 +/- 3.8% of the dose. At the lower dose of 25 micrograms.kg-1, these accounted for 18.6 +/- 3.0 and 36.7 +/- 4.7% of the dose, respectively. Similarly, for rats given CBZ-E (25 micrograms.kg-1), the N-glucuronide of the parent compound was the major metabolite, accounting for 19.1 +/- 4.5% of the dose. O-glucuronides were relatively minor metabolites of both drugs. Glutathione adducts were identified in the bile of both groups of animals. Although these adducts were relatively minor metabolites of CBZ-E (1.8% of the dose), they were more substantial products of the metabolism of CBZ. Three isometric glutathionyl dihydrohydroxy-CBZ adducts were identified by LC/MS. They collectively accounted for 5.8 +/- 0.9% of the dose. In conclusion, we have provided evidence, in rats, for the generation of a reactive arene oxide species from CBZ. If not adequately detoxified, via conjugation with glutathione, this has the potential to initiate cellular damage. In humans, a similar mechanism may be involved in CBZ-associated hypersensitivity.

摘要

在大鼠体内研究了卡马西平(CBZ)及其主要代谢物卡马西平10,11 - 环氧化物(CBZ - E)在人体内的代谢情况。特别着重于对二氢羟基硫加合物的鉴定,这些加合物是活性芳基氧化物中间体的解毒产物。对麻醉并插管的雄性Wistar大鼠静脉注射[³H]CBZ(25微克·千克⁻¹或25毫克·千克⁻¹)或[³H]CBZ - E(25微克·千克⁻¹或25毫克·千克⁻¹),并收集胆汁和尿液5小时。每种给药方案中,尿液中排出的药物不到8%。胆汁排泄分别占给药的CBZ(25微克·千克⁻¹和25毫克·千克⁻¹)的73.7±6.2%和41.8±6.2%(平均值±标准差,N = 4),以及给药的CBZ - E(25微克·千克⁻¹和25毫克·千克⁻¹)的47.6%(N = 2)和28.1±6.0%。CBZ和CBZ - E的主要代谢途径都是N - 葡萄糖醛酸化。在给予CBZ(25毫克·千克⁻¹)的大鼠中,母体化合物的N - 葡萄糖醛酸苷占剂量的12.6±2.6%,而CBZ - E N - 葡萄糖醛酸苷占剂量的12.3±3.8%。在较低剂量25微克·千克⁻¹时,它们分别占剂量的18.6±3.0%和36.7±4.7%。同样,对于给予CBZ - E(25微克·千克⁻¹)的大鼠,母体化合物的N - 葡萄糖醛酸苷是主要代谢物,占剂量的19.1±4.5%。O - 葡萄糖醛酸苷是两种药物相对次要的代谢物。在两组动物的胆汁中都鉴定出了谷胱甘肽加合物。虽然这些加合物是CBZ - E相对次要的代谢物(占剂量的1.8%),但它们是CBZ代谢的更主要产物。通过液相色谱/质谱鉴定出三种等规谷胱甘肽二氢羟基 - CBZ加合物。它们总共占剂量的5.8±0.9%。总之,我们在大鼠中提供了证据,证明CBZ可生成活性芳基氧化物物种。如果不能通过与谷胱甘肽结合充分解毒,这有可能引发细胞损伤。在人类中,类似的机制可能与CBZ相关的超敏反应有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验